Karolinska Development AB has invested SEK 7.5 million in BOOST Pharma’s latest financing round, totaling SEK 15 million. BOOST Pharma is developing BT-101, a stem cell therapy for osteogenesis imperfecta (OI), aiming to reduce fracture frequency in children with the condition. With positive results from the Phase 2 trial, BT-101 is now moving towards a Phase 3 trial. Karolinska Development’s CEO, Viktor Drvota, expresses support for BOOST Pharma’s progress. The company’s ownership in BOOST Pharma is 14 percent.BOOST Pharma aims to provide the first disease-modifying therapy for OI, a condition characterized by fragile bones and fractures.

Read more at GlobeNewswire: Karolinska Development invests SEK 7.5 million to support